1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,260 | 6,280 | 03.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 322 | Business Wire | The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceeds as planned without modification. Consistent good safety profile and tolerability for MaaT033... ► Artikel lesen | |
| 08.01. | MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease | 475 | Business Wire | The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as third-line treatment of aGvHD... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.01. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 272 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 10.12.24 | MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting | 276 | Business Wire | MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) Register here.
Sustained High Response Rates... ► Artikel lesen | |
| 05.12.24 | MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease | 553 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 26.11.24 | MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 67 | Business Wire | MaaT033 administered for two months confirmed good safety profile and was well tolerated in patients with ALS. Other study endpoints will be analysed in the upcoming months with full data... ► Artikel lesen | |
| 07.11.24 | MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD | 423 | Business Wire | Efficacy, safety, and long-term follow-up data from 154 patients in the EAP in Europe further reinforce the excellent clinical profile of MaaT013 in GI-aGvHD.
MaaT013 is a safe and effective... ► Artikel lesen | |
| 05.11.24 | MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes | 318 | Business Wire | Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in the treatment of acute Graft-versus-Host Disease; topline results expected... ► Artikel lesen | |
| 15.10.24 | MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease | 275 | Business Wire | Last patient treated in MaaT Pharma's Phase 3 ARES clinical trial
Topline results publication now expected in January 2025
Positive DSMB review of Phase 3 ARES trial announced in... ► Artikel lesen | |
| 19.09.24 | MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update | 369 | Business Wire | Positive efficacy and safety data of MaaT013 in aGvHD in the Early Access Program presented at the EBMT 2024 annual meeting with 63% GI-ORR at D28, a 49% one year and 42% 18 months Overall Survival... ► Artikel lesen | |
| 09.09.24 | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 413 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 04.09.24 | MaaT Pharma To Present and Participate in Investor and Medical Conferences in September | 354 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies (MET) dedicated to enhancing... ► Artikel lesen | |
| 09.08.24 | MaaT Pharma: MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 526 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 05.07.24 | MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux | 674 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 05.07.24 | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 843 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 02.07.24 | MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 585 | Business Wire | The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceed as planned without modifications. MaaT033 has shown to have an acceptable safety profile and... ► Artikel lesen | |
| 25.06.24 | MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16 | 642 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 24.06.24 | MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer | 339 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 10.06.24 | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 524 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 29.05.24 | MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting | 357 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 9,080 | +0,75 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress | Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,262 | +0,53 % | Pacific Biosciences Of California, Inc. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Pacific Biosciences of California, Inc. (PACB):Earnings: $3.57 million in Q4 vs. -$82.02 million in the same period last year.
EPS:... ► Artikel lesen | |
| CENTOGENE | 0,150 | +25,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,450 | +1,65 % | ICE - ATAI Life Sciences - Das war einfach! - Vorher, nachher | ||
| BIOMERIEUX | 115,60 | +2,30 % | QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology | PARIS (dpa-AFX) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements... ► Artikel lesen | |
| CYCLACEL | 0,310 | -8,82 % | Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership | ||
| SYROS PHARMACEUTICALS | 0,071 | -9,62 % | Syros Pharmaceuticals, Inc. Announces Voluntary Delisting from Nasdaq and SEC Deregistration | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed... ► Artikel lesen | |
| GENUS | 21,600 | +0,93 % | Genus HY Pre-Tax Profit Down; Declares Unchanged Interim Dividend Of 10.3p/shr | LONDON (dpa-AFX) - Genus plc (GNS.L) reported that its profit before tax for the six months ended 31 December 2024 dropped to 3.3 million pounds from last year's 14.3 million pounds. The latest... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,420 | 0,00 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 14,000 | -11,95 % | AnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and... ► Artikel lesen | |
| ABIONYX PHARMA | 1,390 | +9,62 % | ABIONYX Pharma: World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances | Commitment to the LCAT patient community for the creation of a patient association and assistance with early diagnosis Preparation for the submission of the Marketing Authorization Application... ► Artikel lesen | |
| MEIRAGTX | 6,950 | +12,10 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
| METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 8,850 | +2,91 % | Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy | HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,131 | -2,24 % | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2024 | GOTHENBURG, Sweden, February 19, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2024 is now available on the company's... ► Artikel lesen |
Das Unternehmen MAAT PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,140 (-2,30 %) liegt der Kurs bei 5,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.
